SMTL ID : 8bxc.2 (1 other biounit)

Crystal structure of JAK2 JH1 in complex with itacitinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

monomer

Ligands

1 x MLI: MALONATE ION(Non-functional Binders)

MLI.1: 7 residues within 4Å: Chain A: L.33, F.35, E.48, C.50, V.65, K.67, K.110 5 PLIP interactions: 5 interactions with chain A Hydrogen bonds: A:F.35, A:E.48 Salt bridges: A:K.67, A:K.67, A:K.110

1 x S4R: Itacitinib(Non-covalent)

S4R.2: 27 residues within 4Å: Chain A: L.39, G.40, K.41, G.42, N.43, F.44, G.45, S.46, V.47, A.64, K.66, L.68, H.75, E.82, V.95, M.113, E.114, Y.115, L.116, S.120, R.164, N.165, L.167, G.177, D.178, G.180, L.181 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:F.44, A:L.167, A:L.167 Hydrogen bonds: A:F.44, A:G.45, A:E.114, A:L.116 Salt bridges: A:D.178 pi-Stacking: A:F.44 Halogen bonds: A:G.180

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Miao, Y. et al., Structural basis for JAK2 inhibition by clinical stage inhibitors. To Be Published

Release Date

2023-12-20

Peptides

Tyrosine-protein kinase JAK2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Tyrosine-protein kinase JAK2

Related Entries With Identical Sequence